Priorities For The National Action Plan on Combating Antibiotic-Resistant Bacteria: 2020–2025

Presentation on the WG Report

Martin Blaser Mike Apley Lonnie King Kathy Talkington

July 10, 2019



Working Group Members

- Council Members (voting and liaison)
- Interagency CARB Task Force Members
 - HHS: CDC, FDA, AHRQ, CMS, ASPR, ASPE, NIH, OGA
 - DoD, State, USAID, EPA
 - USDA: APHIS, ARS, FSIS



MARTY BLASER

Process

- Tasked by Secretary in September 2018 to identify 3-5 emerging areas within the five NAP goals
- RFI posted for public feedback, January Public meeting held with 31 panelists, then WG met to discuss feedback and distill recommendations to the Secretary
 - Council members developed the recommendations, the Task Force helped inform the process
- Identified 17 distinct recommendations across the five NAP goals




MARTY BLASER

RFI open from November 23, 2018 – January 7, 2019 180 responses from 67 respondents

Report Organization

- Figure in Executive Summary summarizes five major identified priorities (top)
 - Three additional priorities to incorporate across all five goals (bottom)
- Body of the report includes introduction and background, and then provides explanations for each recommendation with sub-bullets, by Goal.





LONNIE KING

SLOW THE EMERGENCE OF RESISTANT BACTERIA AND PREVENT THE SPREAD OF RESISTANT INFECTIONS

- Priority 1: Advance implementation of IP and AS programs through measurable, outcomes-based research.
- Priority 2: Widely implement IP and AS strategies that have been proven effective throughout healthcare settings and animal agriculture.
- Priority 3: Promote AS in companion animal health settings.
- Priority 4: Facilitate and support the adoption of new technologies and management practices that can reduce the need for antibiotic use in animal agriculture.

Priority 5: Increase the use and interoperability of data systems to support AS.



MIKE APLEY

STRENGTHEN NATIONAL ONE HEALTH SURVEILLANCE EFFORTS TO COMBAT RESISTANCE

Priority 1: Enhance antibiotic use and resistance reporting systems for human and animal health.

Priority 2: Expand AMR reporting through NARMS and fund supporting research.

Priority 3: Understand the role of antibiotics and resistance in the environment.



KATHY TALKINGTON

Advance Development and Use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria

Priority 1: Support studies that use clinical outcomes to evaluate the use of diagnostics and advance their integration into care.

Priority 2: Develop incentives and reimbursement strategies to support uptake of diagnostics.

Priority 3: Promote and support the development of new diagnostics and their integration into stewardship and AMR prevention programs in both human and animal health settings.



MIKE APLEY

ACCELERATE BASIC AND APPLIED RESEARCH AND DEVELOPMENT FOR NEW ANTIBIOTICS, OTHER THERAPEUTICS, AND VACCINES

Priority 1: Adopt effective pull incentives for development of new antibiotics, vaccines, and alternatives.

Priority 2: Continue to create push incentives for development of new antibiotics, vaccines, and alternatives.

Priority 3: Advance research on optimal dose and duration of existing antibiotic therapies.

Priority 4: Address shortages of existing antibiotics.



KATHY TALKINGTON

IMPROVE INTERNATIONAL COLLABORATION AND CAPACITIES FOR ANTIMICROBIAL PREVENTION, SURVEILLANCE, CONTROL, AND ANTIMICROBIAL RESEARCH AND DEVELOPMENT

Priority 1: Enhance U.S. leadership in the global fight against AMR.

Priority 2: Promote and support AMR activities in low- and middle- income countries.



MIKE APLEY

Additional Recommendations: Five Years and Beyond

- Integrate antibiotic resistance surveillance systems for One Health surveillance.
- Develop an integrated federal One Health research strategy.
- Develop a national, interagency effort to address antibiotic resistance issues around the globe.



LONNIE KING

Discussion and Vote

